Merck (MRK) Tops Q4 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
BMO Capital Reiterates Market Perform Rating on Merck (MRK) Following Earnings
February 3, 2022 7:46 AM ESTBMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $87.00 price target on Merck (NYSE: MRK), following the company's Q4 earnings report.
The analyst quotes: "Modest best (Rev +4%, Operating Income +5%). While there was an overall beat on revenues this largely came from... More
Cantor Fitzgerald Reiterates Merck (MRK) at Overweight on Earnings, Pipeline and Growth "Remains Underappreciated"
February 3, 2022 7:44 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $107.00 price target on Merck (NYSE: MRK), following the company's Q4 earnings report.
The analyst quotes: "Post a 4Q21 sales and EPS beat, and ahead of a strong outlook for 2022, we are... More
